COR Stock Recent News

Cencora stock reached new highs after its earnings report late January. The drug stock is trading tightly and may be poised for a move.

The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and HQY are set to gain the most.

Here is how Cencora (COR) and Cigna (CI) have performed compared to their sector so far this year.

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Cencora (COR) came out with quarterly earnings of $3.28 per share, beating the Zacks Consensus Estimate of $2.86 per share. This compares to earnings of $2.71 per share a year ago.

Drug distributor Cencora raised its annual profit outlook on Wednesday, betting on strong demand for costly specialty medicines that treat diseases such as cancer and rheumatoid arthritis.

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Besides Wall Street's top -and-bottom-line estimates for Cencora (COR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.